Story perspectives

Bank of America Highlights Pivotal Phase 3 Trials for Novartis

3/24/2026

Summary

Story summary

Bank of America analysts say upcoming phase 3 data for Novartis are pivotal, with failure depressing consensus estimates and success shifting focus from patent expirations.
They highlight phase 3 trials for remibrutinib in relapse-remitting multiple sclerosis and pelacarsen for secondary prevention of cardiovascular events.
Peak annual sales could reach $3.0 billion for remibrutinib and $3.1 billion for pelacarsen, and Bank of America raised its target price to 140 Swiss francs.

1 of 1

Story summary

Bank of America analysts say upcoming phase 3 data for Novartis are pivotal, with failure depressing consensus estimates and success shifting focus from patent expirations.
They highlight phase 3 trials for remibrutinib in relapse-remitting multiple sclerosis and pelacarsen for secondary prevention of cardiovascular events.
Peak annual sales could reach $3.0 billion for remibrutinib and $3.1 billion for pelacarsen, and Bank of America raised its target price to 140 Swiss francs.